Qvt Financial LP Bluebird Bio, Inc. Transaction History

Qvt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $120,092 - $152,556	-3,487 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $94,567 - $160,297	3,487 New	3,487 $213,000
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $91,219 - $221,424	-3,487 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $58,124 - $93,907	902 Added 34.89%	3,487 $549,000
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $243,320 - $311,574	-2,442 Reduced 48.58%	2,585 $406,000
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $202,183 - $288,446	-1,911 Reduced 27.54%	5,027 $858,000
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $882,781 - $1.42 Million	-10,865 Reduced 61.03%	6,938 $1.24 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $1.03 Million - $1.63 Million	17,803	17,803 $2.45 Million

144

63.2M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Qvt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Qvt Financial LP with notifications on news.